(T3104V) The Novel GlycoPEGylated FGF21 Analog, BIO89-100, Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers
Author: Chih-Ming L. Tseng, Ph.D., M.B.A. Co-authors: Moti Rosenstock, PhD, Andrew Pierce, PhD., Elliot Offman, PhD., Will Charlton, M.D., Maya Margalit, M.D., Hank Mansbach, M.D. |
BIO89-100 is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) under development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). FGF21 is an endogenous metabolic hormone that regulates lipid, carbohydrate and energy metabolism; it has a half-life of < 2 hours. The purpose of glycoPEGylation is to prolong half-life, enabling less frequent dosing regimens. Early-development data to support first-time-in-humans trial (FTIH) and FTIH data are reported here.